Fred Holdbrook

452 total citations
16 papers, 312 citations indexed

About

Fred Holdbrook is a scholar working on Physiology, Rheumatology and Organic Chemistry. According to data from OpenAlex, Fred Holdbrook has authored 16 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 7 papers in Rheumatology and 4 papers in Organic Chemistry. Recurrent topics in Fred Holdbrook's work include Lysosomal Storage Disorders Research (10 papers), Glycogen Storage Diseases and Myoclonus (7 papers) and Carbohydrate Chemistry and Synthesis (4 papers). Fred Holdbrook is often cited by papers focused on Lysosomal Storage Disorders Research (10 papers), Glycogen Storage Diseases and Myoclonus (7 papers) and Carbohydrate Chemistry and Synthesis (4 papers). Fred Holdbrook collaborates with scholars based in United States, United Kingdom and Australia. Fred Holdbrook's co-authors include Hans-Peter Hartung, Xavier Montalbán, Tracy Stites, Ludwig Kappos, Jean Pelletier, Frederik Barkhof, Lixin Zhang-Auberson, Bhupendra Khatri, Giancarlo Comi and Gordon Francis and has published in prestigious journals such as Neurology, The Lancet Neurology and The American Journal of Medicine.

In The Last Decade

Fred Holdbrook

13 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fred Holdbrook United States 5 151 98 78 64 59 16 312
Claudia E. Ramirez United States 10 27 0.2× 59 0.6× 49 0.6× 35 0.5× 109 1.8× 16 372
Costas Pantos Greece 10 76 0.5× 137 1.4× 44 0.6× 10 0.2× 90 1.5× 22 305
Miguel Ángel Gómez-Sámano Mexico 9 22 0.1× 122 1.2× 48 0.6× 14 0.2× 24 0.4× 23 311
Liming Zhang China 8 51 0.3× 45 0.5× 38 0.5× 9 0.1× 18 0.3× 21 227
Ahmet Karataş Türkiye 10 30 0.2× 60 0.6× 24 0.3× 18 0.3× 8 0.1× 47 288
Zhongyuan Wen China 11 29 0.2× 104 1.1× 40 0.5× 19 0.3× 68 1.2× 20 299
Qimei Luo China 10 41 0.3× 131 1.3× 16 0.2× 13 0.2× 29 0.5× 21 376
Yukari Mae Japan 12 27 0.2× 52 0.5× 55 0.7× 16 0.3× 13 0.2× 34 310
T. Wagner Germany 12 71 0.5× 51 0.5× 65 0.8× 42 0.7× 5 0.1× 43 351
Shuzhen Sun China 9 16 0.1× 52 0.5× 35 0.4× 9 0.1× 26 0.4× 29 234

Countries citing papers authored by Fred Holdbrook

Since Specialization
Citations

This map shows the geographic impact of Fred Holdbrook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Holdbrook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Holdbrook more than expected).

Fields of papers citing papers by Fred Holdbrook

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Holdbrook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Holdbrook. The network helps show where Fred Holdbrook may publish in the future.

Co-authorship network of co-authors of Fred Holdbrook

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Holdbrook. A scholar is included among the top collaborators of Fred Holdbrook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Holdbrook. Fred Holdbrook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Kushlaf, Hani, Jordi Díaz‐Manera, Drago Bratkovic, et al.. (2025). Switching Enzyme Replacement Therapy for Late‐Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL. Muscle & Nerve. 72(2). 230–239. 1 indexed citations
3.
Kishnani, Priya S., Barry J. Byrne, Kristl G. Claeys, et al.. (2024). Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. Journal of Patient-Reported Outcomes. 8(1). 132–132. 3 indexed citations
4.
Mozaffar, Tahseen, Drago Bratkovic, Barry J. Byrne, et al.. (2024). Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL. Molecular Genetics and Metabolism. 141(2). 107971–107971. 1 indexed citations
5.
Byrne, Barry J., Benedikt Schoser, Priya S. Kishnani, et al.. (2023). Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). Journal of Neurology. 271(4). 1787–1801. 14 indexed citations
6.
Mozaffar, Tahseen, Benedikt Schoser, Priya S. Kishnani, et al.. (2023). Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007). Neurology. 100(17_supplement_2). 1 indexed citations
7.
Byrne, Barry J., Benedikt Schoser, Priya S. Kishnani, et al.. (2023). Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02). Molecular Genetics and Metabolism. 138(2). 107042–107042. 3 indexed citations
8.
Byrne, Barry J., Jordi Díaz‐Manera, Özlem Göker-Alpan, et al.. (2023). P372 Safety of home administration of cipaglucosidase alfa + miglustat in late-onset Pompe disease: results from multiple clinical trials. Neuromuscular Disorders. 33. S151–S151.
9.
Schiffmann, Raphael, Daniel G. Bichet, Ana Jovanović, et al.. (2018). Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet Journal of Rare Diseases. 13(1). 68–68. 25 indexed citations
10.
Nicholls, Kathy, Roberto Giugliani, Raphael Schiffmann, et al.. (2018). Renal outcomes with up to 9 years of migalastat in patients with Fabry disease: Results from an open-label extension study. Molecular Genetics and Metabolism. 123(2). S105–S106.
11.
12.
Radue, Ernst W., Frederik Barkhof, Jeffrey A. Cohen, et al.. (2012). MRI Analyses in RRMS Patients with Highly Active Disease: Results from FREEDOMS and TRANSFORMS Phase 3 Studies (P01.134). Neurology. 78(Meeting Abstracts 1). P01.134–P01.134. 3 indexed citations
13.
Khatri, Bhupendra, Frederik Barkhof, Giancarlo Comi, et al.. (2011). Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology. 10(6). 520–529. 168 indexed citations
14.
Wright, Jackson T., George L. Bakris, David S.H. Bell, et al.. (2007). Lowering Blood Pressure With β‐Blockers in Combination With Other Renin‐Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial. Journal of Clinical Hypertension. 9(11). 842–849. 15 indexed citations
15.
Messerli, Franz H., David S.H. Bell, Vivian Fonseca, et al.. (2007). Body Weight Changes with β-Blocker Use: Results from GEMINI. The American Journal of Medicine. 120(7). 610–615. 75 indexed citations
16.
Cox, Donna S., Jagadeesh Aluri, Elisabeth A. Minthorn, et al.. (2003). Pharmacokinetics (PK) and Pharmacodynamics (PD) of Argatroban in Combination With A GP IIB/IIIA Antagonist in Patients Undergoing Percutaneous Coronary Intervention (PCI). Clinical Pharmacology & Therapeutics. 73(2).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia E. Ramirez Breakdown of academic impact, for papers by Costas Pantos Breakdown of academic impact, for papers by Miguel Ángel Gómez-Sámano Breakdown of academic impact, for papers by Liming Zhang Breakdown of academic impact, for papers by Ahmet Karataş Breakdown of academic impact, for papers by Zhongyuan Wen Breakdown of academic impact, for papers by Qimei Luo Breakdown of academic impact, for papers by Yukari Mae Breakdown of academic impact, for papers by T. Wagner Breakdown of academic impact, for papers by Shuzhen Sun
Rankless by CCL
2026